Revier Therapeutics Raises €6 Million in Seed Funding
Revier Therapeutics, a biotech firm based in Heidelberg, Germany, has announced the successful closing of a €6 million seed funding round on August 25, 2026. The company is pioneering a novel therapeutic approach targeting class IIa histone deacetylases (HDACs) to treat cardiometabolic diseases.
Investors and Leadership
The seed funding round was led by KHAN Technology Transfer Fund II, with additional participation from High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg. This financial backing will bolster Revier Therapeutics' efforts in developing their preclinical pipeline.
Revier Therapeutics was co-founded by Eva van Rooij, who serves as CEO, and Michael Nolan, the CTO. Eva van Rooij stated, "We believe the next generation of cardiometabolic medicines needs to address the underlying disease-driving biology to deliver impactful and long-term solutions for patients."
Use of Funds
The funds raised will be used to further develop Revier's preclinical pipeline, focusing on their lead program in heart failure with preserved ejection fraction (HFpEF) and a secondary program in atherosclerotic cardiovascular disease (ASCVD). The financing will also support the expansion of the company's operational, scientific, and clinical capabilities.
Conclusion
Revier Therapeutics is positioned to advance its innovative approach in treating cardiometabolic diseases, addressing significant unmet needs in cardiovascular medicine. With this new funding, the company aims to rapidly progress its lead therapies toward clinical trials.